Faculty Bibliography

Reconstruction in head and neck surgery requires restoration of complex functions, including speech, swallowing, and breathing, while preserving as much facial form and patient identity as possible. Over the past decade, advances in preoperative digital planning, intraoperative technologies, and robotic platforms have reshaped reconstructive strategies, giving rise to the concept of hybrid reconstruction. Hybrid approaches integrate free tissue transfer with computer-aided design and manufacturing (CAD/CAM), virtual surgical planning, intraoperative navigation, and robot-assisted microsurgery to enhance precision, reproducibility, and functional outcomes. This narrative review examines the principles and applications of hybrid reconstruction in head and neck surgery with particular emphasis on osseous reconstruction of the mandible, maxilla, and midface. The roles of intraoperative navigation and robotic assistance as enabling tools are discussed, along with their potential benefits and current limitations. Functional and morphologic outcomes, patient-reported quality of life, and challenges related to cost, access, training, and evidence heterogeneity are critically reviewed. Hybrid reconstruction represents an advancement toward outcomes-driven, patient-centered care; however, thoughtful integration of emerging technologies and continued emphasis on rigorous outcome assessment are essential to guide responsible adoption in contemporary head and neck reconstructive surgery.

BACKGROUND AND OBJECTIVES/OBJECTIVE:Interactions between cancer cells and their microenvironment are central to tumor formation. Regional microenvironmental variability in the brain may offer insights into essential factors in tumorigenesis. Surprisingly, a granular assessment of regional patterns of gliomagenesis has not been undertaken in the molecular era. The aim of this study was to quantitatively establish the anatomic distribution of the major molecular subtypes of adult diffuse glioma. METHODS:We retrospectively analyzed 204 isocitrate dehydrogenase (IDH)-mutant and 200 IDH-wildtype gliomas. Reproducibility was assessed in an external cohort (190 IDH-mutant, 227 IDH-wildtype), and microarray expressions from Allen Human Brain Atlas were used to compare transcriptomic profiles between IDH-mutant hotspots and coldspots. RESULTS:A total of 50.5% (103/204) of IDH-mutant tumors arose with the superior and middle frontal gyri, indicating a 3.1-fold regional enrichment relative to the volume of these gyri (P < .001). Totally, 9.5% (19/200) of IDH-wildtype tumors arose in the superior temporal gyrus with a 2.1-fold enrichment (P = .01). IDH-mutant and wildtype tumors were enriched by 4 and 4.5-fold, respectively, in the insula (both P < .001). Overall, 23.3% (24/103) of astrocytomas occurred disproportionately higher in the insula compared with oligodendrogliomas (P < .001). Transcriptomic analysis comparing the lobar hotspot (frontal lobe) to the coldspot (occipital lobe) revealed frontal enrichment of cholesterol (normalized enrichment score = 1.78) and fatty acid (normalized enrichment score = 1.94) metabolism pathways, paralleling the observed regional enrichment of IDH-mutant gliomas. CONCLUSION/CONCLUSIONS:This study identifies molecular subtype-specific glioma hotspots and may suggest that regional metabolic differences may underlie the brain's variable vulnerability to gliomagenesis. These findings provide a framework for investigating additional microenvironmental factors that drive human glioma formation.

Facial nerve palsy is a debilitating condition with substantial physical and psychosocial impacts. Facial reanimation encompasses surgical reconstructive procedures aimed at restoring the functions of the facial nerve to improve function and quality of life in patients with facial palsy. This educational review outlines the essential principles for interpreting imaging studies for facial reanimation including fundamental anatomy, technical descriptions and imaging appearances of common reconstructive procedures, and key findings that should be included when reporting studies for patients being considered for facial reanimation. The information provided in this review equips radiologists to contribute effectively to a multidisciplinary team necessary for the treatment of patients with facial nerve palsy.

Oral medicine is the dental specialty dedicated to the oral health care of medically complex patients and the diagnosis and management of medically related diseases, disorders, and conditions affecting the oral and maxillofacial region. Like other dental and medical specialties, oral medicine patient care is often impacted by challenges such as limited manpower, time, or resources. Artificial intelligence (AI) tools seek to supersede these challenges by automating human tasks and ushering greater efficiency and productivity. For direct patient care in oral medicine, AI has applications in risk prediction modeling, diagnosis establishment, treatment decision-making, and prognosis and outcomes prediction modeling.

Oral medicine is the dental specialty dedicated to the oral health of medically complex patients and the diagnosis and management of medically-related diseases, disorders, and conditions affecting the oral and maxillofacial region. In addition to direct patient care, Oral Medicine specialists often engage in indirect patient care activities such as patient education and practice administration and/or academic activities such as student education and research. Artificial intelligence (AI) tools have been increasingly studied to facilitate these domains and contribute to more positive outcomes for practitioners, patients, and students alike. A review of the literature on these AI applications in Oral Medicine and related medical and dental fields provides an understanding of their current advantages and limitations.

OBJECTIVES/UNASSIGNED:This ASPO survey investigates pediatric peri-operative tracheostomy care practices through a nationwide survey. It aims to identify challenges, explore opportunities for standardization across institutions, and recommend strategies that could reduce complications and enhance patient care. METHODS/UNASSIGNED:A 19-question survey was administered online to pediatric otolaryngologists. Descriptive statistics summarized respondent demographics and responses. RESULTS/UNASSIGNED:Of 138 respondents, 90% practiced in the US, primarily in the Mid-Atlantic and Great Lakes. Over 60% performed fewer than 10 pediatric tracheostomies annually. A majority (98%) used stay sutures for accidental decannulation, and 25% did not mature the stoma. Notably, 92% adhered to standardized post-operative protocols. Bivona tracheostomy tubes were most commonly used (72%). First tube changes were typically on postoperative Days 5 and 7, with false passage creation (46%) and bleeding (41%) as primary complications. Routine surveillance bronchoscopy was conducted by 63%, mainly twice in the first year (34%). CONCLUSION/UNASSIGNED:The survey highlights wide variation in pediatric tracheostomy practices and underscores the importance of standardized protocols. Most respondents perform fewer than 10 procedures each year, yet adherence to institutional guidelines reflects a strong commitment to safety. This study identifies key areas of variability such as the timing of the first tube change, use of surveillance bronchoscopy, and reported complications-and outlines opportunities for further research and standardization aimed at improving consistency and clinical outcomes. LEVEL OF EVIDENCE/UNASSIGNED:5.

BACKGROUND:Age-related hearing loss is common and a particularly prevalent disability among Veterans. In response, comprehensive hearing services are available within the Veterans Affairs (VA) integrated healthcare system. Severe hearing loss may pose distinct communication challenges inadequately addressed by hearing aids, but data suggest severe hearing loss is often not treated differently. We sought to identify barriers and facilitators to evidence-based and individualized management of severe hearing loss from the perspectives of VA clinicians and Veterans. METHODS:We used purposeful sampling to conduct remote semi-structured video interviews with 33 current VA clinicians encompassing multiple disciplines and 39 Veterans with severe hearing loss over approximately an 18 month period (May 2022 to December 2023). We analyzed qualitative data using content thematic analysis. Coding categories were summarized within each participant; then across all participants to yield clinician-specific and Veteran themes. RESULTS:In the sample of 33 VA clinicians (20 audiologists, 9 otolaryngologists and 4 primary care clinicians), the overarching theme of qualitative data is that hearing loss is undertreated in the Veteran population. Across clinician groups, the qualitative data revealed multi-level factors (system-, clinician-, and patient-level) that influence the delivery of hearing care and management for Veterans with severe hearing loss. Interviews revealed that efficient access and collaborative care facilitate evidence-based practice. Among Veterans, inadequately managed hearing loss impacts quality of life; lack of knowledge and misconceptions about hearing care options and system-level barriers influence Veterans' perceptions of their hearing care and management. CONCLUSION/CONCLUSIONS:Although hearing care is available to Veterans, multi-level factors influence the delivery of hearing care and management for Veterans with severe hearing loss. Greater attention both in primary and specialty care is needed to ensure tailored treatments are available to Veterans with severe hearing loss across the integrated VA health care system.

INTRODUCTION/UNASSIGNED:The Clinical Toxicology Recommendations Collaborative was established by three international clinical toxicology societies and tasked to produce recommendations on the management of poisonings. The Activated Charcoal in Clinical Toxicology Workgroup (the Workgroup) was formed to provide recommendations on the administration of activated charcoal for gastrointestinal decontamination and enhanced elimination in poisoning. METHODS/UNASSIGNED:Based on a systematic review of the literature, 43 poisons or poison categories were selected for appraisal. Voting statements were drafted using a predetermined format. Strength of consensus was measured using the Disagreement Index as defined by the RAND/University of California at Los Angeles Appropriateness Method. A two-round modified Delphi method was used to reach expert consensus. RESULTS/UNASSIGNED:The Workgroup concluded that there is no role for activated charcoal in poisoning from arsenic, caesium, copper, ethanol, methanol, ethylene glycol, iron, lead, lithium, and metformin. Activated charcoal is appropriate after ingestion of antidysrhythmics (types I and III not discussed specifically), beta-adrenergic antagonists, bupropion, calcium-channel blockers, carbamazepine, cardiac glycosides, chloroquine, cocaine, colchicine, cyanide, dapsone, diphenhydramine, disopyramide, factor Xa inhibitors, ibuprofen, isoniazid, lamotrigine, methotrexate, moclobemide, opioids, organophosphorus insecticides, paracetamol (acetaminophen), paraquat, phenobarbital, phenytoin, quinidine and quinine, salicylates, selective serotonin reuptake inhibitors, sulfonylureas, thallium, theophylline, tricyclic antidepressants, valproic acid, venlafaxine, and warfarin. An additional dose of activated charcoal to complete gastrointestinal decontamination is appropriate after ingestion of carbamazepine, paracetamol, paraquat, phenobarbital, salicylates, thallium, theophylline, valproic acid and verapamil. The maximum time post-ingestion for which activated charcoal administration is recommended differs for each poison and different formulations. According to an individualized risk assessment, activated charcoal is appropriate up to 6 h post-ingestion for many poisons. If ongoing absorption is suspected, which may occur, for example, with pharmacobezoar formation, certain modified-release preparations, or when drug burden exceeds the limits of solubility, then activated charcoal can be administered beyond 6 h post-ingestion for gastrointestinal decontamination. Multiple-dose activated charcoal for enhanced elimination is appropriate in poisoning with carbamazepine, cardiac glycosides, colchicine, dapsone, phenobarbital, phenytoin, thallium and theophylline. UNLABELLED: DISCUSSION/UNASSIGNED:The decision to use activated charcoal is complex and depends primarily on the nature of the poison(s), the time since ingestion, the severity of the symptoms present at the time of decision or expected based on the dose ingested or patient comorbidities, and the availability of antidotes or other treatments. Although the existing level of evidence is primarily of low or very low quality, clinical decisions are still necessary. CONCLUSIONS/UNASSIGNED:The Workgroup recommends the administration of a single-dose of activated charcoal beyond the traditional 1 h post-ingestion time point in selected poisons and introduces the concept of an additional dose of activated charcoal to prevent further absorption of poisons that may remain in the gastrointestinal tract for prolonged periods of time. Multiple-dose activated charcoal is also recommended to enhance elimination in selected clinical scenarios.